Clinical Trial Update: Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial comparing intermittent and maintenance icotinib in combination with pemetrexed/carboplatin versus icotinib alone in EGFR-mutant non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)
• icotinib (icotinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung, Carcinoma | Phase 2 | Status: UNKNOWN